<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ut m_source= Chrome&amp;ff=20230722142603&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;fc=20230708114047<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20230722142603&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 7 月 22 日星期六 18:26:04 +0000</lastbuilddate><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>孤儿质量控制塑造网络动态和基因表达</title><link/>https://pubmed.ncbi.nlm.nih.gov/37478862/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>所有真核生物都需要复杂的蛋白质网络将发育信号转化为准确的细胞命运决定。干扰网络组件之间相互作用的突变通常会导致疾病，但复杂网络的组成和动态如何建立仍然知之甚少。在这里，我们将 E3 连接酶 UBR5 确定为信号中枢，帮助降解在以 c-Myco Protein 为中心的网络中起作用的多个转录调节因子的不配对亚基...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 7 月 14 日：S0092-8674(23)00691-8. doi: 10.1016/j.cell.2023.06.015. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">所有真核生物都需要复杂的蛋白质网络将发育信号转化为准确的细胞命运决定。干扰网络组件之间相互作用的突变通常会导致疾病，但复杂网络的组成和动态如何建立仍然知之甚少。在这里，我们将 E3 连接酶 UBR5 确定为信号中枢，帮助降解在以 c-Myco 蛋白为中心的网络中起作用的多个转录调节因子的不配对亚基。只有在复杂解离时才可用。通过快速翻转不配对的转录因子亚基s，UBR5在转录调节因子之间建立动态相互作用，使细胞能够有效地执行基因表达，同时保持对环境信号的接受性。我们得出结论，孤儿质量控制在建立动态蛋白质网络中起着至关重要的作用，这可能解释了转录过程中蛋白质降解的保守需求，并为调节疾病中的基因表达提供了机会。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37478862/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37478862</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.015>10.1016/j.cell.2023.06.015</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37478862</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator> -凯文·G·马克</dc:creator><dc:creator>斯里杜尔加黛维科拉</dc:creator><dc:creator>雅各布·D·阿吉雷</dc:creator><dc:creator>丹妮尔·M·加肖特</dc:creator><dc:creator>斯特凡·施密特</dc:creator><dc:creator>黛安·L·哈康森</dc:creator><dc:creator>克里斯蒂娜·徐</dc:creator><dc:creator>卢卡斯·凯特</dc:creator><dc:creator>格奥尔格·肯普夫</dc:creator><dc:creator>布伦达·马丁内斯·冈萨雷斯</dc:creator><dc:creator>大卫·阿科皮安</dc:creator><dc:creator>斯蒂芬妮·K·西</dc:creator><dc:creator>尼古拉斯·H·托马</dc:creator><dc:creator>迈克尔·雷普</dc:creator><dc:date>2023-07-21</dc:date><dc:source>细胞</dc:source><dc:title>孤儿质量控制塑造网络动态和基因表达</dc:title><dc:identifier>下午：37478862</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.015</dc:identifier></item><item><title>使用干细胞衍生的类原肠胚将人类发育的植入后阶段建模为早期器官发生</title><link/>https://pubmed.ncbi.nlm.nih.gov/37478861/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>复制人类原肠胚形成的体外干细胞模型已经产生，但它们缺乏胚胎发育、形态发生和模式形成所需的必需的胚胎外细胞。在这里，我们描述了一种稳健而有效的方法，可以促使人类扩展多能干细胞自组织成胚胎样结构，称为类原肠胚细胞，其中包括胚胎（外胚层）和胚胎外（下胚层）组织。尽管类原肠胚细胞由于... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 7 月 19 日：S0092-8674(23)00794-8.doi: 10.1016/j.cell.2023.07.018.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">在这里，我们描述了一种强大而有效的方法，可促使人类扩展多能干细胞自组织成胚胎样结构，称为类原肠胚细胞，其中包括胚胎（外胚层）和胚外（下胚层）组织。该类原肠胚周围平台允许对原肠胚形成之外的进一步探索，并可能有助于用于再生医学的人类胎儿组织的发育。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37478861/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37478861</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.018>10.1016/j.cell.2023.07.018</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37478861</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>刘立中</dc:creator><dc:creator>大浦圣也</dc:creator><dc:creator>——扎卡里·马卡姆</dc:creator><dc:creator>詹姆斯·N·汉密尔顿</dc:creator><dc:creator>罗宾·M·斯科里</dc:creator><dc:creator>李雷杰</dc:creator><dc:creator>樱井正宏</dc:creator><dc:creator>王雷</dc:creator><dc:creator>卡洛斯·平松·阿特亚加</dc:creator><dc:creator>尼古拉斯·普拉赫塔</dc:creator><dc:creator>韩加里</dc:creator><dc:creator>吴军</dc:creator><dc:date>2023-07-21</dc:date><dc:source>细胞</dc:source><dc:title>使用干细胞衍生的类原肠胚将人类发育的植入后阶段建模为早期器官发生</dc:title><dc:identifier>下午：37478861</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.018</dc:identifier></item><item><title>绘制儿童多系统炎症综合征的全身炎症和抗体反应 (MIS-C)</title><link/> https://pubmed.ncbi.nlm.nih.gov/37478820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 7 月 20 日；186(15):3325.doi:10.1016/j.cell.2023.06.012。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37478820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37478820</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.012>10.1016/j.cell.2023.06.012</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37478820</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>康纳·N·格鲁伯</dc:creator><dc:creator>鲁谢尔·帕特尔</dc:creator><dc:creator>丽贝卡·特拉克曼</dc:creator><dc:creator>劳伦·勒波</dc:creator><dc:creator>法蒂玛·阿马纳特</dc:creator><dc:creator>弗洛里安·克莱默</dc:creator><dc:creator>凯伦·M·威尔逊</dc:creator><dc:creator>凯南·奥内尔</dc:creator><dc:creator>丹尼尔·吉农</dc:creator><dc:creator>——凯文·图巴莱斯</dc:creator><dc:creator>马尼什库马尔·帕特尔更多</dc:creator><dc:creator>康斯坦丁诺斯·穆斯卡斯</dc:creator><dc:creator>蒂莫西·奥唐纳</dc:creator><dc:creator>埃利奥特·梅里特</dc:creator><dc:creator>妮可·西蒙斯</dc:creator><dc:creator>凡妮莎·巴塞塞特</dc:creator><dc:creator>黛安·M·德尔·瓦莱</dc:creator><dc:creator>萨曼莎·乌东德姆</dc:creator><dc:creator>古尔帕万·康</dc:creator><dc:creator>查鲁塔·阿加什</dc:creator><dc:creator>内哈·卡雷卡</dc:creator><dc:creator>乔安娜·格拉博斯卡</dc:creator><dc:creator>聂凯</dc:creator><dc:creator>杰西卡·勒贝里切尔</dc:creator><dc:creator>谢慧</dc:creator><dc:creator>诺姆·贝克曼</dc:creator><dc:creator>桑迪普·甘加达兰</dc:creator><dc:creator>乔治·奥福里-阿曼福</dc:creator><dc:creator>尤里·拉森</dc:creator><dc:creator>阿迪布·拉赫曼</dc:creator><dc:creator>金胜熙-舒尔茨</dc:creator><dc:creator>——亚历山大·W·查尼</dc:creator><dc:creator>萨沙·格尼亚提克</dc:creator><dc:creator>布鲁斯·D·盖尔布</dc:creator><dc:creator>米里亚姆·梅拉德</dc:creator><dc:creator>杜桑·博古诺维奇</dc:creator><dc:date>2023-07-21</dc:date><dc:source>细胞</dc:source><dc:title>绘制儿童多系统炎症综合征的全身炎症和抗体反应 (MIS-C)</dc:title><dc:identifier>下午：37478820</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.012</dc:identifier></item><item><title> cGAS-STING 在动物体内的先天免疫感应揭示了意想不到的信使</title><link/>https://pubmed.ncbi.nlm.nih.gov/37478819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description> DNA 传感器 cGAS 及其适配器 STING 构成了一种古老的病原体检测机制，但尚不清楚其功能在整个动物界的保守程度如何。在本期《细胞》杂志中，Kranzusch 及其同事鉴定了数千种 cGAS 样受体，并发现了激活动物先天免疫反应的第二信使网络。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 7 月 20 日；186(15):3145-3147.doi:10.1016/j.cell.2023.06.014。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DNA 传感器 cGAS 及其适配器 STING 构成了一种古老的病原体检测机制，但尚不清楚其功能在整个动物界的保守程度如何。在本期《细胞》杂志中，Kranzusch 及其同事鉴定了数千种 cGAS 样受体，并发现了激活动物先天免疫反应的第二信使网络。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37478819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37478819</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.014>10.1016/j.cell.2023.06.014</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37478819</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>莱昂妮·翁特霍尔兹纳</dc:creator><dc:date>2023-07-21</dc:date><dc:source>细胞</dc:source><dc:title>cGAS-STING 在动物体内的先天免疫感应揭示了意想不到的信使</dc:title><dc:identifier>下午：37478819</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.014</dc:identifier></item><item><title>染料照亮活体人类胚胎发生</title><link/>https://pubmed.ncbi.nlm.nih.gov/37478818/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>辅助生殖在全球范围内呈上升趋势。细胞形态学通常用于胚胎选择，但早期植入前发育的细胞生物学仍然知之甚少。在本期《Cell》中，Domingo-Muelas 等人揭示了人类胚胎的新特征，这对植入前基因检测具有重要意义。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 7 月 20 日；186(15):3143-3145.doi:10.1016/j.cell.2023.06.011。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">辅助生殖在全球范围内呈上升趋势。细胞形态学通常用于胚胎选择，但早期植入前发育的细胞生物学仍然知之甚少。在本期《Cell》中，Domingo-Muelas 等人揭示了人类胚胎的新特征，这对植入前基因检测具有重要意义。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37478818/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37478818</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.011>10.1016/j.cell.2023.06.011</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37478818</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>阿黛尔·阿尔·乔德</dc:creator><dc:creator>玛丽-海伦·韦尔哈克</dc:creator><dc:date>2023-07-21</dc:date><dc:source>细胞</dc:source><dc:title>染料照亮活体人类胚胎发生</dc:title><dc:identifier>下午：37478818</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.011</dc:identifier></item><item><title> STEM 领域的亚裔美国人并非铁板一块</title><link/>https://pubmed.ncbi.nlm.nih.gov/37478817/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>尽管存在巨大的多样性，但 STEM 中的亚裔美国人被分组并被视为同质的整体，面临着刻板印象和差异。我们提出的解决方案包括分解亚裔美国人群体并承认由亚裔美国人组成的不同种族亚群体，以在 STEM 领域实施变革。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 7 月 20 日；186(15):3138-3142.doi:10.1016/j.cell.2023.06.017。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">尽管存在巨大的多样性，但 STEM 中的亚裔美国人被分组并被视为同质的整体，面临着刻板印象和差异。我们提出的解决方案包括分解亚裔美国人群体并承认由亚裔美国人组成的不同种族亚群体，以在 STEM 领域实施变革。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37478817/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37478817</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.017>10.1016/j.cell.2023.06.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37478817</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>泽尔维埃</dc:creator><dc:creator>贾旺</dc:creator><dc:creator>能维</dc:creator><dc:creator>维杰瓦尔丹·卡玛伦蓬迪</dc:creator><dc:creator>泰勒·巴隆根</dc:creator><dc:creator>布莱恩娜·邵</dc:creator><dc:creator>黄阳</dc:creator><dc:creator>拉里·范</dc:creator><dc:creator>我的视觉</dc:creator><dc:creator>南希·王</dc:creator><dc:creator>邵建强</dc:creator><dc:creator>库琳·安·库姆斯</dc:creator><dc:creator>普拉珊娜·卡蒂</dc:creator><dc:creator>刘凯华</dc:creator><dc:creator>吉村凯莉</dc:creator><dc:creator>米歇尔·比特</dc:creator><dc:creator>戴道福</dc:creator><dc:creator>马克·菲利普斯</dc:creator><dc:creator>——理查德·贝林格</dc:creator><dc:date>2023-07-21</dc:date><dc:source>细胞</dc:source><dc:title>STEM 领域的亚裔美国人并非铁板一块</dc:title><dc:identifier>下午：37478817</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.017</dc:identifier></item><item><title>呼吸道合胞病毒 Prefusion F 疫苗</title><link/>https://pubmed.ncbi.nlm.nih.gov/37478816/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>呼吸道合胞病毒 (RSV) 是成人严重呼吸道感染的最常见原因。再感染很常见，包括老年人。六十年来，有效的婴儿疫苗仍然难以找到。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 7 月 20 日；186(15):3137-3137.e1.doi:10.1016/j.cell.2023.05.048。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">呼吸道合胞病毒 (RSV) 是成人严重呼吸道感染的最常见原因。再感染很常见，包括老年人。六十年来，有效的婴儿疫苗仍然难以找到。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37478816/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37478816</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.05.048>10.1016/j.cell.2023.05.048</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37478816</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——安·R·福西</dc:creator><dc:creator>-爱德华·E·沃尔什</dc:creator><dc:date>2023-07-21</dc:date><dc:source>细胞</dc:source><dc:title>呼吸道合胞病毒 Prefusion F 疫苗</dc:title><dc:identifier>下午：37478816</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.05.048</dc:identifier></item><item><title>心血管和痴呆症预防：分数、饮食和康复的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37477627/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 《欧洲心脏杂志》2023 年 7 月 21 日；44(28):2501-2505.doi: 10.1093/eurheartj/ehad449。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477627/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37477627</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad449>10.1093/eurheartj/ehad449</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477627</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>菲利波·克雷亚</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心血管和痴呆症预防：分数、饮食和康复的作用</dc:title><dc:identifier>下午：37477627</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad449</dc:identifier></item><item><title>心脏病康复和二级预防的全球视角：心血管护理及相关专业协会、欧洲预防心脏病学协会和国际心血管预防和康复理事会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37477626/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>心血管疾病是导致死亡、发病、残疾、健康相关生活质量下降以及全球经济负担的主要原因，约 80% 的疾病负担发生在低收入和中等收入国家 (LMIC)。随着患有症状性疾病的人寿命越来越长，二级预防和康复卫生服务的有效性和可及性变得前所未有的重要。虽然 LMIC 经历了最高的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 《欧洲心脏杂志》2023 年 7 月 21 日；44(28):2515-2525.doi: 10.1093/eurheartj/ehad225。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心血管疾病是死亡、发病、残疾、健康相关生活质量下降以及全球经济负担的主要原因，约 80% 的疾病负担发生在低收入和中等收入国家 (LMIC)。随着患有症状性疾病的人寿命越来越长，二级预防和康复卫生服务的有效性和可及性变得前所未有的重要。这篇最先进的综述提供了关于心脏康复和二级预防的当代全球视角，对比了高收入国家和地区的挑战和机遇。与低收入环境相比。提供了克服中低收入国家心脏康复的系统、临床医生、项目和患者层面障碍的可行解决方案。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477626/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37477626</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10361025/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">PMC10361025</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad225>10.1093/eurheartj/ehad225</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477626</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>罗德·S·泰勒</dc:creator><dc:creator>苏珊·弗雷德里克斯</dc:creator><dc:creator>——伊恩·琼斯</dc:creator><dc:creator>利斯·纽贝克</dc:creator><dc:creator>朱莉·桑德斯</dc:creator><dc:creator>诺埃米·德·斯图茨 (Noemi De Stoutz)</dc:creator><dc:creator> ——大卫·R·汤普森</dc:creator><dc:creator>迪普蒂·瓦德瓦</dc:creator><dc:creator>雪莉·L·格雷斯</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心脏病康复和二级预防的全球视角：心血管护理及相关专业协会、欧洲预防心脏病学协会和国际心血管预防和康复理事会的科学声明</dc:title><dc:identifier>下午：37477626</dc:identifier><dc:identifier> PMC：PMC10361025</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad225</dc:identifier></item><item><title>标准替格瑞洛和普拉格雷治疗（无降阶梯策略）出血风险的比较</title><link/>https://pubmed.ncbi.nlm.nih.gov/37477371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 21:ehad432.doi: 10.1093/eurheartj/ehad432. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37477371</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad432>10.1093/eurheartj/ehad432</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477371</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>塞尔丘克森</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>标准替格瑞洛和普拉格雷治疗（无降阶梯策略）出血风险的比较</dc:title><dc:identifier>下午：37477371</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad432</dc:identifier></item><item><title>使用院前和肽素和院内肌钙蛋白加速排除急性心肌梗死：AROMI 研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37477353/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>结论：与使用 0 小时/3 小时排除策略相比，联合使用院前和肽素和首次院内高敏肌钙蛋白 T 加速 AMI 双标志物排除可缩短住院时间，且不会增加 30 天主要不良心脏事件的发生率。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 21:ehad447.doi: 10.1093/eurheartj/ehad447. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：目前的急性心肌梗死 (AMI) 排除策略受到心肌肌钙蛋白延迟时间释放的挑战。和肽素是内源性应激的非特异性生物标志物，在 AMI 早期升高，涵盖肌钙蛋白仍正常的早期阶段。AROMI 试验旨在评估加速双标志物排除策略是否可以安全地缩短早期排除 AMI 后出院患者的住院时间。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法和结果：被救护车送往医院的疑似 AMI 患者按 1:1 随机分配，要么使用院前血样中测量的和肽素和到达医院时测量的高敏肌钙蛋白 T 进行加速排除，要么使用 0 小时/3 小时排除策略进行标准排除。AROMI 研究纳入了 4351 名疑似 AMI 患者。0.9 小时（95% 置信区间 0.7-1.1 小时）排除 AMI 后出院的患者，与标准排除相比，30 天主要不良心脏事件不较差（绝对风险差 -0.4%，95% 置信区间 -2.5 至 1.7；非劣效 P 值 = 0.013）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与使用 0 小时/3 小时排除策略相比，联合使用院前和肽素和首次院内高敏肌钙蛋白 T 加速 AMI 双标志物排除可缩短住院时间，且不会增加 30 天主要不良心脏事件的发生率。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477353/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37477353</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad447>10.1093/eurheartj/ehad447</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477353</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>克劳斯·克亚尔·佩德森</dc:creator><dc:creator>卡斯滕·斯坦加德</dc:creator><dc:creator>莫滕·辛格曼·博特克</dc:creator><dc:creator>汉娜·马尔·桑德加德</dc:creator><dc:creator>凯伦·卡埃·多特</dc:creator><dc:creator>克里斯蒂安·尤尔·特克尔森</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>使用院前和肽素和院内肌钙蛋白加速排除急性心肌梗死：AROMI 研究</dc:title><dc:identifier>下午：37477353</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad447</dc:identifier></item><item><title>血管壁功能和年龄相关疾病的体细胞突变</title><link/>https://pubmed.ncbi.nlm.nih.gov/37477347/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 21:ehad454.doi: 10.1093/eurheartj/ehad454. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477347/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37477347</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad454>10.1093/eurheartj/ehad454</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477347</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>格瓦迪斯·雷维肯</dc:creator><dc:creator>拉拉·加西亚·美利奴</dc:creator><dc:creator>彼得·马赫特尔</dc:creator><dc:creator>玛丽亚埃里克森</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>血管壁功能和年龄相关疾病的体细胞突变</dc:title><dc:identifier>下午：37477347</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad454</dc:identifier></item><item><title>新证据支持血流动力学引导的心力衰竭充血远程管理</title><link/>https://pubmed.ncbi.nlm.nih.gov/37477224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 21:ehad435.doi: 10.1093/eurheartj/ehad435. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37477224</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad435>10.1093/eurheartj/ehad435</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477224</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>丹妮拉·佩迪西诺</dc:creator><dc:creator>马西莫·沃尔普</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>新证据支持血流动力学引导的心力衰竭充血远程管理</dc:title><dc:identifier>下午：37477224</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad435</dc:identifier></item><item><title>心房颤动的风险是否应该阻止 PFO 封堵治疗隐源性缺血性中风？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37477208/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 21:ehad425.doi: 10.1093/eurheartj/ehad425. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477208/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37477208</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad425>10.1093/eurheartj/ehad425</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477208</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>约翰·卡姆</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心房颤动的风险是否应该阻止 PFO 封堵治疗隐源性缺血性中风？</dc:title><dc:identifier>下午：37477208</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad425</dc:identifier></item><item><title>基于既往试验的标准替格瑞洛和普拉格雷疗法的比较</title><link/>https://pubmed.ncbi.nlm.nih.gov/37477206/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 21:ehad433.doi: 10.1093/eurheartj/ehad433. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477206/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37477206</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad433>10.1093/eurheartj/ehad433</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477206</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>姜至勋</dc:creator><dc:creator>朴庆宇</dc:creator><dc:creator>金孝秀</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>基于既往试验的标准替格瑞洛和普拉格雷疗法的比较</dc:title><dc:identifier>下午：37477206</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad433</dc:identifier></item><item><title>左主 PCI：小心抑扬符！</title><link/> https://pubmed.ncbi.nlm.nih.gov/37477204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 21:ehad434.doi: 10.1093/eurheartj/ehad434. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37477204</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad434>10.1093/eurheartj/ehad434</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477204</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>尼尔斯·P·约翰逊</dc:creator><dc:creator>安正民</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>左主 PCI：小心抑扬符！</dc:title><dc:identifier>下午：37477204</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad434</dc:identifier></item><item><title> EGFR/IGF1R 信号传导调节肥厚型心肌病的松弛</title><link/>https://pubmed.ncbi.nlm.nih.gov/37477020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>结论：我们展示了筛选心肌细胞舒张和收缩的功能调节剂的可行性，我们观察到这些参数分别受 EGFR/IGF1R、Akt、细胞周期信号传导和 FoxO（叉头盒 O 类）信号传导相关激酶的调节。将筛选数据与 HCM 患者组织中的磷酸蛋白质组学分析相结合表明，抑制 EGFR/IGF1R 信号传导是治疗 HCM 松弛的有希望的靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 21 日。doi：10.1161/CIRCRESAHA.122.322133。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：舒张功能障碍是射血分数保留的心力衰竭和肥厚性心肌病 (HCM) 等疾病的核心。然而，改善心脏舒张的治疗方法很少，部分原因是对心肌细胞舒张调节剂的了解有限。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们优化并提高了空载起酥油测量的通量，并在野生型小鼠分离的成年心肌细胞中筛选了激酶抑制剂库。筛选了 157 种激酶抑制剂，并在纯合子<i>MYBPC3</i> <sub>c.2373insG</sub> HCM 小鼠模型的心肌细胞中进行了验证。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在野生型 (n=33) 心肌细胞 (n=24 563) 中筛选 157 种激酶抑制剂，结果鉴定出 17 种正性肌力药物和 21 种阳性强心剂，几乎全部都是新的。通过对 HCM 患者心肌（n=24 名 HCM 和 n=8 名供者）进行磷酸蛋白质组学分析，我们证明 EGFR/IGFR1 簇的 8 种蛋白中的 6 种的激活增加我们在小鼠 HCM (n=12) 心肌细胞 (n=2023) 中验证了该簇中的化合物。该簇中的三种化合物能够改善 HCM 心肌细胞的松弛。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们展示了筛选心肌细胞舒张和收缩的功能调节剂的可行性，我们观察到这些参数分别受 EGFR/IGF1R、Akt、细胞周期信号传导和 FoxO（叉头盒 O 类）信号传导相关激酶的调节。将筛选数据与 HCM 患者组织中的磷酸蛋白质组学分析相结合表明，抑制 EGFR/IGF1R 信号传导是治疗 HCM 松弛的有希望的靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37477020</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.122.322133>10.1161/CIRCRESAHA.122.322133</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477020</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>西拉·阿尔古尔</dc:creator><dc:creator>麦克·舒尔特</dc:creator><dc:creator>艾美·曼德斯</dc:creator><dc:creator>瓦伦汀·詹森</dc:creator><dc:creator>萨斯基亚·施洛萨雷克</dc:creator><dc:creator>理查德·德·戈伊·德·哈斯</dc:creator><dc:creator>亚历克斯·亨尼曼</dc:creator><dc:creator>桑德·R·皮尔斯玛</dc:creator><dc:creator>康妮·R·希门尼斯</dc:creator><dc:creator>米歇尔·米歇尔</dc:creator><dc:creator>露西·开利</dc:creator><dc:creator>米歇尔·赫尔姆斯</dc:creator><dc:creator>乔兰达·范德维尔登</dc:creator><dc:creator>迪德里克·WD·库斯特</dc:creator><dc:date>2023-07-21</dc:date><dc:source>流通研究</dc:source><dc:title>EGFR/IGF1R 信号传导调节肥厚型心肌病的松弛</dc:title><dc:identifier>下午：37477020</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.322133</dc:identifier></item><item><title>肺栓塞的新型预测模型：从二分算法到个性化可能性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37475706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 21:ehad392.doi: 10.1093/eurheartj/ehad392. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37475706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37475706</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad392>10.1093/eurheartj/ehad392</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37475706</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>托马斯·A·泽尔尼克</dc:creator><dc:creator>艾琳·M·朗</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>肺栓塞的新型预测模型：从二分算法到个性化可能性</dc:title><dc:identifier>下午：37475706</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad392</dc:identifier></item><item><title>急性冠状动脉综合征和经皮冠状动脉介入治疗中双重抗血小板治疗的降级或缩写：冠状动脉血栓形成国际专家组的共识声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37474795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description>对于接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者，传统的双重抗血小板治疗 (DAPT) 包括阿司匹林和强效 P2Y 嘌呤受体 12 (P2Y(12)) 抑制剂（普拉格雷或替格瑞洛），疗程为 12 个月。）常规剂量的抑制剂可以... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 7 月 20 日。doi：10.1038/s41569-023-00901-2。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y purinoceptor 12 (P2Y <sub>12</sub> ) inhibitor (prasugrel or ticagrelor) for 12 months. Although this approach reduces ischaemic risk, patients are exposed to a substantial risk of bleeding. Strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y <sub>12</sub> inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. Either strategy requires assessment of the ischaemic and bleeding risks of each individual. De-escalation of DAPT intensity can reduce bleeding without increasing ischaemic events and can be guided by platelet function testing or genotyping. Abbreviation of DAPT duration after 1-6 months, followed by monotherapy with aspirin or a P2Y <sub>12</sub> inhibitor, reduces bleeding without an increase in ischaemic events in patients at high bleeding risk, particularly those without high ischaemic risk. However, these two strategies have not yet been compared in a head-to-head clinical trial. In this Consensus Statement, we summarize the evidence base for these treatment approaches, provide guidance on the assessment of ischaemic and bleeding risks, and provide consensus statements from an international panel of experts to help clinicians to optimize these DAPT approaches for individual patients to improve outcomes.</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37474795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37474795</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00901-2>10.1038/s41569-023-00901-2</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37474795</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>戴安娜·戈罗格</dc:creator><dc:creator>何塞·路易斯·费雷罗</dc:creator><dc:creator>英戈·阿伦斯</dc:creator><dc:creator>亚子纯也</dc:creator><dc:creator>托比亚斯·盖斯勒</dc:creator><dc:creator>西格伦·霍尔沃森</dc:creator><dc:creator>库尔特·胡贝尔</dc:creator><dc:creator>郑英勋</dc:creator><dc:creator>埃利亚诺·P·纳瓦雷塞</dc:creator><dc:creator>安德里亚·鲁博利</dc:creator><dc:creator>德克·西宾</dc:creator><dc:creator>乔兰塔·M·西勒-马图拉</dc:creator><dc:creator>罗伯特·F·斯托里</dc:creator><dc:creator>——杰克·WC·谭</dc:creator><dc:creator>朱里恩·M·滕伯格</dc:creator><dc:creator>马可·瓦尔吉米利</dc:creator><dc:creator>克里斯托夫·范登布里埃勒</dc:creator><dc:creator>格雷戈里·YH·利普</dc:creator><dc:date>2023-07-20</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>急性冠状动脉综合征和经皮冠状动脉介入治疗中双重抗血小板治疗的降级或缩写：冠状动脉血栓形成国际专家组的共识声明</dc:title><dc:identifier>下午：37474795</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00901-2</dc:identifier></item><item><title> 2023 年 AHA/ACC/ACCP/ASPC/NLA/PCNA 慢性冠心病患者管理指南：美国心脏协会/美国心脏病学会临床实践指南联合委员会报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/37471501/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230722142603&amp;v=2.17.9.post6+86293ac<description> AIM 《2023 年 AHA/ACC/ACCP/ASPC/NLA/PCNA 慢性冠心病患者管理指南》更新并巩固了自《2012 年 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS 稳定型缺血性心脏病患者诊断和管理指南》以及相应的《2014 年 ACC/AHA/AATS/PCNA/SCAI/S TS 焦点》以来的新证据编辑了稳定型缺血性心脏病患者诊断和管理指南的更新。”方法综合... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 20 日。doi：10.1161/CIR.0000000000001168。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> AIM The &quot;2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease&quot; provides an update to and consolidates new evidence since the &quot;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease&quot; and the corresponding &quot;2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease.&quot; Methods A comprehensive literature search was conducted from September 2021 to May 2022. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Structure This guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. Relevant topics include general approaches to treatment decisions, guideline-directed management and therapy to reduce symptoms and future cardiovascular events, decision-making pertaining to revascularization in patients with chronic coronary disease, recommendations for management in special populations, patient follow-up and monitoring, evidence gaps, and areas in need of future research. Where applicable, and based on availability of cost-effectiveness data, cost-value recommendations are also provided for clinicians. Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37471501/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37471501</a> | DOI: <a href=https://doi.org/10.1161/CIR.0000000000001168>10.1161/CIR.0000000000001168</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37471501</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Salim S Virani</dc:creator><dc:creator> L Kristin Newby</dc:creator><dc:creator> Suzanne V Arnold</dc:creator><dc:creator> Vera Bittner</dc:creator><dc:creator> LaPrincess C Brewer</dc:creator><dc:creator> Susan Halli Demeter</dc:creator><dc:creator> Dave L Dixon</dc:creator><dc:creator> William F Fearon</dc:creator><dc:creator> Beverly Hess</dc:creator><dc:creator> Heather M Johnson</dc:creator><dc:creator> Dhruv S Kazi</dc:creator><dc:creator> Dhaval Kolte</dc:creator><dc:creator> Dharam J Kumbhani</dc:creator><dc:creator> Jim LoFaso</dc:creator><dc:creator> Dhruv Mahtta</dc:creator><dc:creator> Daniel B Mark</dc:creator><dc:creator> Margo Minissian</dc:creator><dc:creator> Ann Marie Navar</dc:creator><dc:creator> Amit R Patel</dc:creator><dc:creator> Mariann R Piano</dc:creator><dc:creator> Fatima Rodriguez</dc:creator><dc:creator> Amy W Talbot</dc:creator><dc:creator> Viviany R Taqueti</dc:creator><dc:creator> Randal J Thomas</dc:creator><dc:creator> Sean van Diepen</dc:creator><dc:creator> Barbara Wiggins</dc:creator><dc:creator> Marlene S Williams</dc:creator><dc:date> 2023-07-20</dc:date><dc:source> Circulation</dc:source><dc:title> 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title><dc:identifier> pmid:37471501</dc:identifier><dc:identifier> doi:10.1161/CIR.0000000000001168</dc:identifier></item><item><title> Correction to: Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations</title><link/> https://pubmed.ncbi.nlm.nih.gov/37471489/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722142603&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Jul 21;133(3):e49. doi: 10.1161/RES.0000000000000623. Epub 2023 Jul 20.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37471489/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722142603&v=2.17.9.post6+86293ac">37471489</a> | DOI: <a href=https://doi.org/10.1161/RES.0000000000000623>10.1161/RES.0000000000000623</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37471489</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-20</dc:date><dc:source> Circulation research</dc:source><dc:title> Correction to: Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations</dc:title><dc:identifier> pmid:37471489</dc:identifier><dc:identifier> doi:10.1161/RES.0000000000000623</dc:identifier></item></channel></rss>